KR101028927B1 - 환원된 표면활성제의 제조를 위한 개선된 합성 지질 혼합체 및 그 제조방법 - Google Patents
환원된 표면활성제의 제조를 위한 개선된 합성 지질 혼합체 및 그 제조방법 Download PDFInfo
- Publication number
- KR101028927B1 KR101028927B1 KR1020047018528A KR20047018528A KR101028927B1 KR 101028927 B1 KR101028927 B1 KR 101028927B1 KR 1020047018528 A KR1020047018528 A KR 1020047018528A KR 20047018528 A KR20047018528 A KR 20047018528A KR 101028927 B1 KR101028927 B1 KR 101028927B1
- Authority
- KR
- South Korea
- Prior art keywords
- surfactant
- reduced
- dppc
- popg
- surfactants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004094 surface-active agent Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 6
- 150000002632 lipids Chemical class 0.000 title description 11
- 238000002360 preparation method Methods 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 16
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims abstract description 9
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 230000004064 dysfunction Effects 0.000 claims abstract description 5
- 239000003580 lung surfactant Substances 0.000 claims abstract description 4
- 208000024891 symptom Diseases 0.000 claims abstract 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 38
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 37
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 15
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 claims description 7
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- -1 oleyl phosphatidylglycerol Chemical compound 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 108010040201 Polymyxins Proteins 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 1
- 229940066294 lung surfactant Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000241 respiratory effect Effects 0.000 abstract 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 36
- 235000021314 Palmitic acid Nutrition 0.000 description 18
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940092456 curosurf Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229940063649 survanta Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Preparation And Processing Of Foods (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002MI001058A ITMI20021058A1 (it) | 2002-05-17 | 2002-05-17 | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| ITMI02A001058 | 2002-05-17 | ||
| PCT/EP2003/004937 WO2003097695A1 (en) | 2002-05-17 | 2003-05-12 | Improved synthetic lipid mixtures for the preparation of a reconstituted surfactant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050016408A KR20050016408A (ko) | 2005-02-21 |
| KR101028927B1 true KR101028927B1 (ko) | 2011-04-12 |
Family
ID=11449919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047018528A Expired - Lifetime KR101028927B1 (ko) | 2002-05-17 | 2003-05-12 | 환원된 표면활성제의 제조를 위한 개선된 합성 지질 혼합체 및 그 제조방법 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7511011B2 (enExample) |
| EP (1) | EP1506234B1 (enExample) |
| JP (1) | JP4883906B2 (enExample) |
| KR (1) | KR101028927B1 (enExample) |
| CN (1) | CN100347193C (enExample) |
| AT (1) | ATE353919T1 (enExample) |
| AU (1) | AU2003233320B2 (enExample) |
| CA (1) | CA2486152C (enExample) |
| CY (1) | CY1106667T1 (enExample) |
| DE (1) | DE60311798T2 (enExample) |
| DK (1) | DK1506234T3 (enExample) |
| EA (1) | EA007928B1 (enExample) |
| ES (1) | ES2282627T3 (enExample) |
| HR (1) | HRP20041058B1 (enExample) |
| IL (2) | IL165239A0 (enExample) |
| IT (1) | ITMI20021058A1 (enExample) |
| MA (1) | MA27960A1 (enExample) |
| MX (1) | MXPA04011369A (enExample) |
| NZ (1) | NZ536606A (enExample) |
| PL (1) | PL209649B1 (enExample) |
| PT (1) | PT1506234E (enExample) |
| SI (1) | SI1506234T1 (enExample) |
| TN (1) | TNSN04219A1 (enExample) |
| UA (1) | UA79609C2 (enExample) |
| WO (1) | WO2003097695A1 (enExample) |
| ZA (1) | ZA200409215B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| RU2380356C2 (ru) | 2003-03-24 | 2010-01-27 | Актимис Фармасьютикалз, Инк. | Производные 2-фенокси и 2-фенилсульфонамида с ссr3 антагонистической активностью для лечения астмы и других воспалительных или иммунологических заболеваний |
| EP1481665A1 (en) * | 2003-05-30 | 2004-12-01 | CHIESI FARMACEUTICI S.p.A. | Novel lipid mixtures for synthetic surfactants |
| UA76074C2 (en) * | 2005-11-09 | 2006-06-15 | O V Palladin Inst Of Biochemis | Calmophil, pharmaceutical composition for substitution therapy aimed at recovering malfunctioned surfactant system of lungs |
| MY148127A (en) | 2006-10-13 | 2013-02-28 | Chiesi Farma Spa | Reconstituted surfactants having improved properties |
| AU2008232677B2 (en) | 2007-03-29 | 2013-09-19 | National Jewish Health | Surfactant lipids, compositions thereof, and uses thereof |
| EP1997502A1 (en) * | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
| EP2022798A1 (en) | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Synthetic pulmonary surfactant peptides |
| EP2281574B1 (en) | 2008-04-02 | 2014-07-09 | The University of Tokushima | Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same |
| US8399406B2 (en) * | 2009-06-05 | 2013-03-19 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C) |
| BR112013004395A2 (pt) * | 2010-08-30 | 2019-09-24 | Hoffmann La Roche | tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização |
| RU2014108240A (ru) | 2011-08-25 | 2015-09-27 | Ф. Хоффманн-Ля Рош Аг | Укороченный тетранектин-аполипопротеин а-i гибридный белок, содержащая его липидная частица и их применения |
| WO2014079898A1 (en) | 2012-11-21 | 2014-05-30 | Chiesi Farmaceutici S.P.A. | Reconstituted pulmonary surfactants |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047623A1 (en) | 1999-02-12 | 2000-08-17 | Chiesi Farmaceutici S.P.A. | Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant |
| WO2001076619A1 (en) | 2000-04-12 | 2001-10-18 | Altana Pharma Ag | Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69407292T2 (de) * | 1993-06-30 | 1998-06-25 | Genentech Inc | Verfahren zur herstellung von liposomen |
| AU2322097A (en) * | 1996-03-27 | 1997-10-17 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
| WO2001076617A2 (en) * | 2000-03-15 | 2001-10-18 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| EP1997502A1 (en) | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
| EP2022798A1 (en) | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Synthetic pulmonary surfactant peptides |
-
2002
- 2002-05-17 IT IT2002MI001058A patent/ITMI20021058A1/it unknown
-
2003
- 2003-05-12 US US10/512,869 patent/US7511011B2/en not_active Expired - Lifetime
- 2003-05-12 KR KR1020047018528A patent/KR101028927B1/ko not_active Expired - Lifetime
- 2003-05-12 PT PT03727469T patent/PT1506234E/pt unknown
- 2003-05-12 IL IL16523903A patent/IL165239A0/xx unknown
- 2003-05-12 PL PL372751A patent/PL209649B1/pl unknown
- 2003-05-12 CA CA2486152A patent/CA2486152C/en not_active Expired - Lifetime
- 2003-05-12 NZ NZ536606A patent/NZ536606A/en not_active IP Right Cessation
- 2003-05-12 ES ES03727469T patent/ES2282627T3/es not_active Expired - Lifetime
- 2003-05-12 MX MXPA04011369A patent/MXPA04011369A/es active IP Right Grant
- 2003-05-12 HR HRP20041058AA patent/HRP20041058B1/hr not_active IP Right Cessation
- 2003-05-12 DK DK03727469T patent/DK1506234T3/da active
- 2003-05-12 DE DE60311798T patent/DE60311798T2/de not_active Expired - Lifetime
- 2003-05-12 SI SI200330756T patent/SI1506234T1/sl unknown
- 2003-05-12 AU AU2003233320A patent/AU2003233320B2/en not_active Expired
- 2003-05-12 WO PCT/EP2003/004937 patent/WO2003097695A1/en not_active Ceased
- 2003-05-12 JP JP2004506367A patent/JP4883906B2/ja not_active Expired - Lifetime
- 2003-05-12 EP EP03727469A patent/EP1506234B1/en not_active Expired - Lifetime
- 2003-05-12 EA EA200401385A patent/EA007928B1/ru unknown
- 2003-05-12 AT AT03727469T patent/ATE353919T1/de active
- 2003-05-12 CN CNB038112531A patent/CN100347193C/zh not_active Expired - Lifetime
- 2003-12-05 UA UA20041109233A patent/UA79609C2/uk unknown
-
2004
- 2004-11-11 TN TNP2004000219A patent/TNSN04219A1/en unknown
- 2004-11-16 IL IL165239A patent/IL165239A/en active IP Right Grant
- 2004-11-16 MA MA27946A patent/MA27960A1/fr unknown
- 2004-11-17 ZA ZA200409215A patent/ZA200409215B/xx unknown
-
2007
- 2007-04-26 CY CY20071100558T patent/CY1106667T1/el unknown
-
2008
- 2008-03-06 US US12/043,177 patent/US7842664B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047623A1 (en) | 1999-02-12 | 2000-08-17 | Chiesi Farmaceutici S.P.A. | Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant |
| WO2001076619A1 (en) | 2000-04-12 | 2001-10-18 | Altana Pharma Ag | Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7842664B2 (en) | Synthetic lipid mixtures for the preparation of a reconstituted surfactant | |
| KR101516443B1 (ko) | 개선된 특성을 가지는 재구성된 계면활성제 | |
| JP4754073B2 (ja) | 表面活性をもつ人工ペプチドおよび人工のサーファクタントの製造におけるその使用 | |
| JP3644035B2 (ja) | 新規な合成ペプチド，それを含有する肺サーファクタント及び呼吸窮迫症候群治療剤 | |
| KR101721309B1 (ko) | 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물 | |
| KR101784651B1 (ko) | 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물 | |
| HK1079221B (en) | Improved synthetic lipid mixtures for the preparation of a reconstituted surfactant | |
| JPWO2005105111A1 (ja) | 人工肺サーファクタント組成物およびその使用方法 | |
| HK1140420B (en) | Reconstituted surfactants having improved properties | |
| HK1185274B (en) | Reconstituted surfactants having improved properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20041116 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080509 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100531 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20110129 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20110405 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20110405 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20140402 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140402 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180403 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180403 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200421 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210401 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230323 Start annual number: 13 End annual number: 13 |
|
| PC1801 | Expiration of term |
Termination date: 20231112 Termination category: Expiration of duration |